




## [12] Patent

[11] Patent No.: GC 0000256	Number of the Decision to Grant the Patent: 6/874
[45] Date of Publishing the Grant of the Patent: 01/11/2006 6/2006	Date of the Decision to Grant the Patent: 18/06/2006
[21] Application No.: GCC/P/2000/702 [22] Filing Date: 07/06/2000 [30] Priority: [31] Priority No. [32] Priority date [33] State 99111126.1 08/06/1999 EP [72] Inventors: 1- Alexander Alanine, 2- Serge Burner, 3- Bernd Büttelmann, 4- Marie-Paule Heitz Neidhart, 5- Georg Jaeschke, 6- Emmanuel Pinard, 7- René Wyler [73] Owner: F. Hoffmann – La Roche AG, 124 Grenzacherstrasse, CH-4070 Basle, Switzerland [74] Agent: Nassir Ali Kadasa	[51] Int. Cl. <sup>7</sup> : C07D 211/46, 211/30; A61K 31/445; A61P 25/00 [56] Cited Documents: - WO 9723216 A (WARNER-LAMBERT CO.) 03 July 1997 - EP 0824098 A (F. HOFFMANN-LA ROCHE AG) 18 February 1998 - WO 9525721 A (SCHERING AG) 28 September 1995

[54] ETHANESULFONYL - PIPERIDINE DERIVATIVES

[57] Abstract: The invention relates to compounds of the general formula



Wherein

R signify hydrogen or hydroxy; R<sup>2</sup> signify hydrogen or methyl; and X signify —O- or —CH<sub>2</sub>-; and their pharmaceutically acceptable acid addition salts. It has been shown that these compounds have a good affinity to the NMDA receptor and they are therefore useful in the treatment of diseases, wherein the therapeutic indications include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.

No. of claims: 14